Choosing between targeted therapies for rheumatoid arthritis patients

The oncology perspective

Tim Bongartz

Research output: Contribution to journalArticle

Abstract

Over the last decade, protein-based pharmaceuticals, so called "biologics", have greatly expanded the therapeutic armamentarium for the treatment of rheumatoid arthritis (RA). Because antiinflammatory therapies with biologics do have multifaceted interactions with pathways involved in carcinogenesis, concerns have been raised that these agents may induce or accelerate malignant growth. Safety analyses based on clinical trial data and observational studies are facing major methodological challenges inherent to the attempt of addressing a possible impact of biologic therapies on a sparse and multi factorial event such as cancer. The expanding palette of approved biologics for the treatment of RA does add additional complexity and raises the issue of how different biologic therapies may compare to each other in terms of their oncogenic effects. This question is of particular importance in patients who have a history of previous malignancy or who develop a cancer while receiving a biologic agent. This review summarizes the published data relevant to a possible link between different biologic agents and malignancies. It explores the question of whether there is enough evidence to support preference of a particular biologic agent over another in different clinical scenarios.

Original languageEnglish (US)
Pages (from-to)70-76
Number of pages7
JournalCurrent Rheumatology Reviews
Volume7
Issue number1
DOIs
StatePublished - 2011

Fingerprint

Biological Therapy
Rheumatoid Arthritis
Biological Factors
Biological Products
Neoplasms
Therapeutics
Observational Studies
Carcinogenesis
Anti-Inflammatory Agents
Clinical Trials
Safety
Growth
Pharmaceutical Preparations
Proteins

Keywords

  • Biologics
  • Malignancy
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Choosing between targeted therapies for rheumatoid arthritis patients : The oncology perspective. / Bongartz, Tim.

In: Current Rheumatology Reviews, Vol. 7, No. 1, 2011, p. 70-76.

Research output: Contribution to journalArticle

@article{55eac7c076f64ecca720779347426c65,
title = "Choosing between targeted therapies for rheumatoid arthritis patients: The oncology perspective",
abstract = "Over the last decade, protein-based pharmaceuticals, so called {"}biologics{"}, have greatly expanded the therapeutic armamentarium for the treatment of rheumatoid arthritis (RA). Because antiinflammatory therapies with biologics do have multifaceted interactions with pathways involved in carcinogenesis, concerns have been raised that these agents may induce or accelerate malignant growth. Safety analyses based on clinical trial data and observational studies are facing major methodological challenges inherent to the attempt of addressing a possible impact of biologic therapies on a sparse and multi factorial event such as cancer. The expanding palette of approved biologics for the treatment of RA does add additional complexity and raises the issue of how different biologic therapies may compare to each other in terms of their oncogenic effects. This question is of particular importance in patients who have a history of previous malignancy or who develop a cancer while receiving a biologic agent. This review summarizes the published data relevant to a possible link between different biologic agents and malignancies. It explores the question of whether there is enough evidence to support preference of a particular biologic agent over another in different clinical scenarios.",
keywords = "Biologics, Malignancy, Rheumatoid arthritis",
author = "Tim Bongartz",
year = "2011",
doi = "10.2174/157339711794474594",
language = "English (US)",
volume = "7",
pages = "70--76",
journal = "Current Rheumatology Reviews",
issn = "1573-3971",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Choosing between targeted therapies for rheumatoid arthritis patients

T2 - The oncology perspective

AU - Bongartz, Tim

PY - 2011

Y1 - 2011

N2 - Over the last decade, protein-based pharmaceuticals, so called "biologics", have greatly expanded the therapeutic armamentarium for the treatment of rheumatoid arthritis (RA). Because antiinflammatory therapies with biologics do have multifaceted interactions with pathways involved in carcinogenesis, concerns have been raised that these agents may induce or accelerate malignant growth. Safety analyses based on clinical trial data and observational studies are facing major methodological challenges inherent to the attempt of addressing a possible impact of biologic therapies on a sparse and multi factorial event such as cancer. The expanding palette of approved biologics for the treatment of RA does add additional complexity and raises the issue of how different biologic therapies may compare to each other in terms of their oncogenic effects. This question is of particular importance in patients who have a history of previous malignancy or who develop a cancer while receiving a biologic agent. This review summarizes the published data relevant to a possible link between different biologic agents and malignancies. It explores the question of whether there is enough evidence to support preference of a particular biologic agent over another in different clinical scenarios.

AB - Over the last decade, protein-based pharmaceuticals, so called "biologics", have greatly expanded the therapeutic armamentarium for the treatment of rheumatoid arthritis (RA). Because antiinflammatory therapies with biologics do have multifaceted interactions with pathways involved in carcinogenesis, concerns have been raised that these agents may induce or accelerate malignant growth. Safety analyses based on clinical trial data and observational studies are facing major methodological challenges inherent to the attempt of addressing a possible impact of biologic therapies on a sparse and multi factorial event such as cancer. The expanding palette of approved biologics for the treatment of RA does add additional complexity and raises the issue of how different biologic therapies may compare to each other in terms of their oncogenic effects. This question is of particular importance in patients who have a history of previous malignancy or who develop a cancer while receiving a biologic agent. This review summarizes the published data relevant to a possible link between different biologic agents and malignancies. It explores the question of whether there is enough evidence to support preference of a particular biologic agent over another in different clinical scenarios.

KW - Biologics

KW - Malignancy

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=79551669331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551669331&partnerID=8YFLogxK

U2 - 10.2174/157339711794474594

DO - 10.2174/157339711794474594

M3 - Article

VL - 7

SP - 70

EP - 76

JO - Current Rheumatology Reviews

JF - Current Rheumatology Reviews

SN - 1573-3971

IS - 1

ER -